Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Disciplined Growth Investors Inc. MN

Disciplined Growth Investors Inc. MN reduced its holdings in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 39.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 766,308 shares of the biotechnology company's stock after selling 490,781 shares during the period. Disciplined Growth Investors Inc. MN owned about 0.67% of Coherus BioSciences worth $797,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Los Angeles Capital Management LLC increased its holdings in Coherus BioSciences by 344.1% in the third quarter. Los Angeles Capital Management LLC now owns 930,132 shares of the biotechnology company's stock valued at $967,000 after buying an additional 720,672 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Coherus BioSciences during the second quarter worth about $1,246,000. Marshall Wace LLP grew its position in Coherus BioSciences by 177.3% in the 2nd quarter. Marshall Wace LLP now owns 420,326 shares of the biotechnology company's stock valued at $727,000 after buying an additional 268,763 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Coherus BioSciences by 159.2% during the 2nd quarter. Renaissance Technologies LLC now owns 394,828 shares of the biotechnology company's stock worth $683,000 after buying an additional 242,500 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in shares of Coherus BioSciences by 304.9% in the 2nd quarter. XTX Topco Ltd now owns 271,433 shares of the biotechnology company's stock valued at $470,000 after buying an additional 204,391 shares during the period. 72.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. HC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Coherus BioSciences in a research report on Wednesday, December 4th. StockNews.com lowered Coherus BioSciences from a "buy" rating to a "hold" rating in a research note on Saturday, October 19th. UBS Group downgraded Coherus BioSciences from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $4.00 to $1.50 in a research note on Friday, August 16th. Finally, Robert W. Baird boosted their target price on Coherus BioSciences from $4.00 to $6.00 and gave the stock an "outperform" rating in a research report on Thursday, December 5th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Coherus BioSciences has an average rating of "Moderate Buy" and an average price target of $5.38.

Coherus BioSciences Trading Down 1.2 %

Shares of Coherus BioSciences stock traded down $0.02 during mid-day trading on Tuesday, hitting $1.68. 2,398,282 shares of the stock were exchanged, compared to its average volume of 3,309,479. The stock has a market capitalization of $193.55 million, a price-to-earnings ratio of -21.25 and a beta of 0.86. Coherus BioSciences, Inc. has a twelve month low of $0.66 and a twelve month high of $3.70. The company has a 50-day simple moving average of $1.00 and a 200 day simple moving average of $1.31.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.